Clinica Doctor Balcangiu-Stroescu

Shock wave therapy in erectile dysfunction – myth or real solution?

Shock wave therapy in erectile dysfunction – myth or real solution?
Useful information
April 13, 2026Valentin Iordache

Introduction

In recent years, shockwave therapy has become increasingly popular in the treatment of erectile dysfunction. Promoted as a modern, non-invasive method capable of treating the cause of the problem, not just the symptoms, this therapy raises an important question:

Is it truly effective or just a medical trend?

The answer is nuanced and depends on the type of erectile dysfunction and the patient's profile.

What is shockwave therapy?

Low-intensity shockwave therapy (Li-ESWT) is a non-invasive procedure that uses acoustic waves applied at the level of the penis.

Its purpose is:

  • improving blood circulation
  • stimulating vascular regeneration

Unlike conventional treatments, this method targets the vascular cause of erectile dysfunction.

How does it work?

Shockwaves produce micro-stimulation at the tissue level that determines:

1. Angiogenesis (new vessel formation)

  • increase in the number of blood vessels
  • improvement of penile blood flow

2. Improvement of endothelial function

  • increased nitric oxide production
  • more efficient vasodilation

3. Tissue regeneration

  • activation of repair mechanisms
  • improvement of erectile tissue quality

For whom is it effective?

Shockwave therapy is most effective in vascular-caused erectile dysfunction, especially:

  • patients with diabetes in early stages
  • patients with mild to moderate erectile dysfunction
  • patients who respond partially to oral treatment

In these cases, it can significantly improve erectile function.

When is it NOT sufficient?

Effectiveness is limited in:

  • severe diabetic neuropathy
  • advanced erectile dysfunction
  • severe vascular impairment
  • very low testosterone (untreated)

In these situations, combination with other treatments is necessary.

How is the treatment performed?

  • the procedure is non-invasive
  • does not require anesthesia
  • takes approximately 15–20 minutes

Usual protocol:

  • 6–12 sessions
  • 1–2 sessions per week

Treatment is performed on an outpatient basis.

Is it painful?

NO

  • patients experience only mild discomfort
  • requires no recovery

How effective is it?

Studies show:

  • significant improvement in 50–70% of patients
  • better results in early stages
  • effects that can last months or years

It does not work for all patients, but it has real results in selected cases.

Advantages

✔️ non-invasive
✔️ no medications
✔️ no major side effects
✔️ treats vascular cause
✔️ can reduce dependency on pills

Disadvantages

  • requires multiple sessions
  • higher costs
  • variable results
  • not effective in all cases

Myth or reality?

❌ Myth:

It is a miraculous solution that works for all patients

✔️ Reality:

It is an effective therapy for a selected group of patients

Role in diabetes

In diabetic patients, effectiveness depends on:

  • glycemic control
  • stage of disease
  • degree of vascular involvement

Can it replace conventional treatment?

NOT completely

But it can:

  • improve response to treatment
  • reduce medication requirements

When should it be considered?

  • mild to moderate erectile dysfunction
  • partial response to oral treatment
  • patient willing to try a modern treatment

Conclusion

Shockwave therapy is not a myth, but neither is it a universal solution.

It is a modern method, effective in selected cases, that can improve erectile function by acting on the vascular cause.

If you are dealing with erectile dysfunction and looking for a modern, non-invasive solution, shockwave therapy may be a suitable option.

Schedule a consultation for evaluation and personalized recommendation.

Also Read

Related Articles

A single injection for cholesterol — from dreams to first human results
Useful information

A single injection for cholesterol — from dreams to first human results

A Phase 1 trial published in the New England Journal of Medicine (November 2025) brings remarkable results: a single infusion of CTX310, a CRISPR-Cas9 therapy developed by Cleveland Clinic and CRISPR Therapeutics, reduced LDL cholesterol by up to 49% and triglycerides by up to 55% in patients with refractory dyslipidemia — without serious adverse events. The mechanism is unique: instead of blocking a protein or interfering with its mRNA, CTX310 permanently edits the ANGPTL3 gene in hepatic cells, mimicking a natural mutation associated with reduced cardiovascular risk throughout life. The therapy is currently in Phase 1b clinical stage, with updates expected in the second half of 2026. It is not approved and does not replace current treatments. Read the full article for clinical context, comparison with statins and PCSK9 inhibitors, and what these data mean for patients. Medical Disclaimer This article presents results from a Phase 1 clinical trial in an early-stage research phase. The therapy described is not approved and is not available as standard treatment. The information is for educational purposes only. Consult your physician for any medical decision.

June 1, 2026Andra-Elena Balcangiu-Stroescu

Ready to schedule?

Book an appointment online or call us directly.

+40 747 777 107